Immunome, Inc. (IMNM)

Immunome Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	217.71	653.48	143.35	98.68	20.32	49.23
Short-Term Investments	302.29	-	73.95	39.46	-	-
Cash & Short-Term Investments	520	653.48	217.3	138.14	20.32	49.23
Cash Growth	94.00%	200.72%	57.30%	579.73%	-58.72%	23.80%
Accounts Receivable	-	-	-	-	-	1.64
Other Receivables	2.7	-	-	-	0.85	2.67
Receivables	2.7	-	-	-	0.85	4.31
Prepaid Expenses	15.75	7.3	4.04	6.56	1.03	2.51
Other Current Assets	-	-	-	-	0.45	0.59
Total Current Assets	538.45	660.78	221.34	144.7	22.65	56.64
Property, Plant & Equipment	21.3	17.61	14.39	3.64	0.97	0.86
Long-Term Deferred Charges	-	-	-	-	0.33	0.33
Other Long-Term Assets	5.63	4.8	4.51	0.2	0.1	0.1
Total Assets	565.38	683.19	240.24	148.54	24.05	57.93

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	6	3.34	14.19	3.31	2.4	3.08
Accrued Expenses	26.34	38.03	25.14	6.98	4.62	4.31
Current Portion of Leases	0.15	-	0.06	0.31	0.23	-
Current Unearned Revenue	-	-	6.94	10.49	-	-
Other Current Liabilities	3.23	3.63	7.98	0.73	0.09	2.34
Total Current Liabilities	35.71	44.99	54.31	21.83	7.33	9.73
Long-Term Leases	4.59	3.86	4.77	1.34	0.06	-
Long-Term Unearned Revenue	-	-	-	5.49	-	-
Other Long-Term Liabilities	-	-	-	-	-	0.01
Total Liabilities	40.3	48.85	59.08	28.66	7.39	9.74

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.01	0.01	0.01	0	0	0
Additional Paid-In Capital	1,381	1,362	696.87	342.66	132.65	127.29
Retained Earnings	-855.13	-728.16	-515.77	-222.81	-116	-79.11
Comprehensive Income & Other	-0.33	-	0.06	0.02	-	-
Total Common Equity	525.08	634.34	181.17	119.88	16.65	48.19
Shareholders' Equity	525.08	634.34	181.17	119.88	16.65	48.19
Total Liabilities & Equity	565.38	683.19	240.24	148.54	24.05	57.93

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	4.74	3.86	4.83	1.65	0.29	-
Net Cash (Debt)	515.26	649.63	212.47	136.49	20.03	49.23
Net Cash Growth	95.25%	205.75%	55.67%	581.37%	-59.31%	25.74%
Net Cash Per Share	5.03	7.44	3.62	6.88	1.65	4.27
Filing Date Shares Outstanding	113.58	113.13	86.95	59.69	12.22	12.13
Total Common Shares Outstanding	113.4	113.13	64.46	43.25	12.13	12.11
Working Capital	502.74	615.79	167.03	122.87	15.32	46.91
Book Value Per Share	4.63	5.61	2.81	2.77	1.37	3.98
Tangible Book Value	525.08	634.34	181.17	119.88	16.65	48.19
Tangible Book Value Per Share	4.63	5.61	2.81	2.77	1.37	3.98
Machinery	-	11.29	9.93	5.75	3.94	3.69
Construction In Progress	-	5.55	3.3	-	-	-
Leasehold Improvements	-	4.16	1.64	0.23	0.19	0.19

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 24, 2026

Data Sources Report a data error